buchspektrum Internet-Buchhandlung

Neuerscheinungen 2011

Stand: 2020-01-07
Schnellsuche
ISBN/Stichwort/Autor
Herderstraße 10
10625 Berlin
Tel.: 030 315 714 16
Fax 030 315 714 14
info@buchspektrum.de

Anshu Agarwal

Nanoformulation and Controlled Delivery of Low Solubility Cancer Drugs


A nanotechnology based approach for formulation of toxic Therapeutic and Imaging Agents
2011. 144 S.
Verlag/Jahr: VDM VERLAG DR. MÜLLER 2011
ISBN: 3-639-32555-9 (3639325559)
Neue ISBN: 978-3-639-32555-3 (9783639325553)

Preis und Lieferzeit: Bitte klicken


This book on nanoformulation of cancer drugs provides a naotechnology based practical approach towards solving the current problems of uncontrollable drug delivery and adverse effects associated with systemic chemotherapy. The research is applied on common chemotherapy drugs like Paclitaxel´ and Tamoxifen´ but not limited to therapeutic agents, as nanoformulation of Gadolinium´, a MRI contrast agent is also described here. This work was performed at the nanotechnology labs of LA Tech University´s well known "Institute for Micromanufacturing" (IFM),USA, under the guidance of one of the pioneers in this field, Dr. Yuri M. Lvov. Part of this work was featured as the cover story in 7th issue of the international pharmaceutical magazine "Pharma Focus Asia" as "R&D @ NANO LEVEL" in 2008 and also published in peer reviewed journals including the well celebrated drug delivery medical journal "Journal of Controlled Release." This research counted towards a US Patent application and received national level funding. In the April 2009 issue of IFM Newsletter, the author has been quoted as "A person who is a brilliant professional both in engineering and medicine."
Dr. Agarwal is currently a Nuclear Medicine House Staff Physician at UTSWMC, Dallas. He is a medical graduate from University of Mumbai(Bombay) and received post graduate medical training from LSUHSC, USA. His research interests earned him MS and PhD in Biomedical Engineering from LA Tech University with work on nanoformulation of cancer drugs.